Emeritus director and roughly ten percent owner Jack W. Schuler increased his stake in Biodesix Inc (NASDAQ:BDSX) by acquiring 82,465 shares of the company's common stock on January 22, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
The purchase prices for the block ranged from $10.675 to $11.10 per share, resulting in a total disclosed transaction value of $903,560. The filing shows that after this acquisition the Jack W. Schuler Living Trust held 1,463,210 shares in total. Schuler is named as the sole trustee of that living trust.
The Form 4 also reported that the Jack W. Schuler 2025 GRAT holds 750,000 shares, with Schuler again identified as sole trustee.
Company financial update
In a separate disclosure, Biodesix released preliminary financial results for the fourth quarter and full year of 2025. The company reported fourth-quarter revenue of $28.8 million, a 41% increase compared with the same quarter a year earlier. Based on those preliminary figures, Biodesix estimates full-year 2025 revenue of $88.5 million, representing a 24% rise versus the prior year and exceeding the company’s previously raised guidance range of $84 million to $86 million.
Those top-line gains contrast with results reported for the third quarter of 2025, when Biodesix posted an earnings per share loss of $1.16, missing the consensus forecast of a $0.06 loss. Revenue in that third quarter was reported at $21.8 million, which exceeded expectations.
Following the third-quarter disclosure, Canaccord Genuity maintained a Buy rating on Biodesix, assigning a price target of $20.00. The firm highlighted improvements in test volumes and revenue, attributing some of the gains to stronger average selling prices and improved payer dynamics.
Interpretation and relevance
The insider purchase by a long-standing director and material shareholder comes alongside preliminary company results that show accelerating revenue growth and an upward revision to full-year revenue outcomes. The prior-quarter EPS shortfall remains a distinct data point for investors assessing near-term profitability versus revenue momentum.
Additional details on the Form 4 and the company’s final audited results were not included in the filings summarized here.